Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Miami-Fort Lauderdale-Pompano Beach, FL MSA — September 2026
Miami regulatory and data roles outprice the nation as talent tightens.
Miami's Clinical Data Manager pay ($142,800) now runs nearly $20,000 above the national median while Biostatistician pay ($86,317) trails the national figure ($133,322) by a similar margin, even as metro unemployment holds at 3.7% against 4.1% nationally.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Miami metro unemployment: 3.7% — vs 4.1% national, 4.5% Florida
- Miami-Dade wage growth: 5.1% YoY — vs 2.5% national advertised wage growth
- Florida minimum wage: $15.00/hr — Effective Sept 30, 2026, up from $14.00
- Miami life sciences talent rank: 20th of 74 — National metro talent concentration ranking
Key takeaways
Clinical Data Manager pay in Miami now exceeds the national rate.
Metro median of $142,800 sits nearly $20,000 above the national $123,031 figure, even as national demand for this role is softening. Miami employers appear to be bidding up a role tied to decentralized trial infrastructure and GLP-1 pipeline data volume, a signal worth testing against actual requisition volume before assuming it reflects structural scarcity.
Biostatistician pay diverges sharply from the national trend.
Metro median fell to $86,317 against a national figure of $133,322 that is rising moderately, a gap wide enough to suggest Miami employers are either drawing from a lower-cost regional talent pool or systematically underpricing a role gaining national urgency as trial complexity increases. Retention risk rises if remote-eligible Miami-based biostatisticians benchmark against national, not local, postings.
Regulatory Affairs pay strength confirms a national bottleneck, locally.
Metro median of $105,142 now runs ahead of the national $104,000 figure, consistent with national reporting that VP-level regulatory talent with first-in-class BLA/NDA experience commands $320K-$580K amid acute global scarcity. Miami organizations managing EU MDR or accelerated FDA pathways should expect this premium to persist regardless of broader hiring slowdowns elsewhere in biopharma.
Lab Technician wage decline tracks the minimum wage squeeze, not demand.
Metro and national Lab Technician pay both declined moderately even as Florida's minimum wage rose to $15.00/hr on September 30, compressing the spread between entry-level scientific roles and unskilled labor. Compensation strategy for entry-tier lab roles may need recalibration to maintain a credible differential above minimum wage, particularly in Miami-Dade where overall wages are climbing 5.1% annually.
Median advertised pay by role — Miami-Fort Lauderdale-Pompano Beach, FL MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $87,113 | $124,800 | $128,981 | Significant increase | $131,354 |
| Clinical Research Associate | $57,200 | $64,692 | $72,895 | Moderate increase | $90,956 |
| Lab Technician | $37,440 | $45,028 | $55,200 | Moderate decline | $47,402 |
| Regulatory Affairs Specialist | $70,081 | $105,142 | $118,456 | Moderate increase | $104,000 |
| Clinical Data Manager | $142,800 | $142,800 | $150,039 | Stable | $123,031 |
| Biostatistician | $68,049 | $86,317 | $94,356 | Moderate decline | $133,322 |
| Validation Engineer | $88,781 | $100,173 | $134,933 | Stable | $108,377 |
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Miami-Fort Lauderdale-West Palm Beach held at 3.7% unemployment in August, the tightest labor market in South Florida and well below the 4.1% national and 4.5% state rates, while Miami-Dade compensation costs climbed 5.1% year-over-year against a national wage growth pace of roughly 2.5-3.2%. Florida's minimum wage increase to $15.00/hr on September 30 compresses the pay band for lab support and entry-level technician roles, pushing total rewards pressure upward from the bottom of the scale at the same moment specialized scientific and regulatory talent remains scarce at the top.
What it means
Tight general labor supply combined with a 20th-place national ranking for life sciences talent concentration means Miami employers compete simultaneously against finance, tech, and healthcare for credentialed professionals, while CRO/CDMO partners draw from the same thin regulatory and CMC talent pool life sciences leaders are trying to build internally. Clinical Research Associate pay has risen moderately locally but still trails the national median by roughly $26,000, suggesting Miami employers either accept longer vacancy cycles or lean further into outsourced clinical operations to bridge the gap. Organizations should evaluate whether build-vs-outsource tradeoffs for regulatory and clinical functions reflect true Miami-specific scarcity or simply national pay benchmarks applied without local adjustment.
Looking ahead
Potential inflection point: Florida's minimum wage reaching $15.00/hr on September 30 compresses entry-level lab and technician pay bands; watch whether Miami biotech and device employers raise technician rates to preserve differentiation from minimum-wage roles across other sectors.
Emerging pressure point: National biopharma layoffs (BioMarin, Bristol Myers) are concentrated in consolidation functions, not execution roles; watch whether released regulatory or CMC talent surfaces in the Miami candidate pool, given the metro's 20th-place national ranking for life sciences talent concentration.
Worth watching: Miami-Dade finance and insurance wages grew 9.8% year-over-year while Broward finance wages declined, a divergence that may pull specialized quantitative talent (biostatisticians, HEOR) away from life sciences employers competing on pay alone in Miami-Dade specifically.
Early indicator: GLP-1 pipeline expansion is driving national demand for bioprocess automation engineers and manufacturing/CMC specialists; track whether Florida's CDMO and device manufacturing base begins advertising comparable premiums, which would signal Miami entering a build-vs-outsource inflection for biologics capacity.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.